# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k062152   
B. Purpose for Submission: Clearance for new intended use   
C. Measurand: Calibrator for Creatine kinase MB isoenzyme   
D. Type of Test: Calibrator   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: Dimension Creatine Kinase MB Isoenzyme Verifier, Model DC27

G. Regulatory Information:

<table><tr><td>Product Code</td><td>Classification</td><td>Regulation Section</td><td>Panel</td></tr><tr><td>Calibrator,</td><td>Class II</td><td>21 CFR 862.1150,</td><td>75 CLINICAL</td></tr><tr><td>Secondary (JIT)</td><td></td><td>Calibrator.</td><td>CHEMISTRY (CH)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use:

The Creatine Kinase MB Isoenzyme Verifier is an in vitro diagnostic product for verification of the Creatine Kinase MB Isoenzyme (CKMB) method on the Dimension $\textsuperscript { \textregistered }$ clinical chemistry system and Dimension Vista™ System.

3. Special conditions for use statement(s): For professional use.

4. Special instrument requirements: Dimension $\textsuperscript { \textregistered }$ clinical chemistry system and Dimension Vista™ System.

# I. Device Description:

CKMB Verifier is a lyophilized human serum base product. Level 1 contains no CKMB, Levels 2 and 3 contain CKMB from a simian heart source. The kit consists of six vials, two vials per level. The volume per vial is $1 . 0 \mathrm { m L }$ .

All human source material was tested by FDA-approved methods for the presence of antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2), Hepatitis B Surface Antigen $\left( { \mathrm { H B s A g } } \right)$ and antibodies to Hepatitis C Virus (HCV) and found to be negative/non-reactive.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Creatine Kinase MB Isoenzyme Verifier

2. Predicate K number (s): k863840

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Creatine Kinase MBIsoenzyme</td><td rowspan=1 colspan=1>Creatine Kinase MB Isoenzyme</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Lyophilized</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Dimension® clinical chemistrysystem values.</td><td rowspan=1 colspan=1>Dimension® clinical chemistrysystem values.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum based productcontaining CKMB from simianheart source.</td><td rowspan=1 colspan=1>Human serum based productcontaining CKMB from simianheart source.</td></tr><tr><td rowspan=1 colspan=1>Number of levels</td><td rowspan=1 colspan=1>Three levels.</td><td rowspan=1 colspan=1>Three levels.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indicationsfor Use</td><td rowspan=1 colspan=1>The Creatine Kinase MB IsoenzymeVerifier is an in vitro diagnosticproduct for verification of theCreatine Kinase MB Isoenzyme(CKMB) method on theDimension® clinical chemistrysystem and Dimension VistaTMSystem.</td><td rowspan=1 colspan=1>The Creatine Kinase MBIsoenzyme Verifier is an in vitrodiagnosticproduct for verification of theCreatine Kinase MB Isoenzyme(CKMB) method on theDimension® clinical chemistrysystem.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>Medical devices - Application of risk management to medical devices (14971:2000)</td></tr></table>

<table><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=1 colspan=1>Guidance for Industry -Abbreviated 510(k) Submissionsfor In Vitro DiagnosticCalibrators; Final</td><td rowspan=1 colspan=1>OIVD</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/calibrator.html</td></tr><tr><td rowspan=2 colspan=1>Guidance for Industry and FDAStaff - Use of Symbols on Labelsand in Labeling of In VitroDiagnostic Devices Intended forProfessional Use</td><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ocd/guidance/444.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

L. Test Principle: Not applicable.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Not applicable.   
b. Linearity/assay reportable range: Not applicable.   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability and Value Assignment: Purified cynomolgus monkey heart CKMB stock solution is added to human serum based matrix. The solution is tested on a Dimension clinical chemistry system with fixed calibration parameters (coefficients) that are determined from the molar absorbidity of NADH. The commercial lot is made by taking calculated quantities of stock solution and adding to human serum base to create the target concentrations for the two calibrator levels. The concentration of each level is verified to be within acceptable range using a Dimension clinical chemistry system with fixed calibration parameters (coefficients) that are determined from the molar absorbidity of NADH.

Stability: Shelf life for the CKMB isoenzyme verifier is 12 months when stored at the recommended conditions. Reconstituted product is stable for 8 hours when stored at $4 \mathrm { { } ^ { \circ } C }$ . Stability study protocols and acceptance criteria were described and found to be acceptable.

d. Detection limit: Not applicable.   
e. Analytical specificity: Not applicable.   
f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: Not applicable.   
b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.